Mainz Biomed NV
MYNZ
Company Profile
Business description
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company’s flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
Contact
Robert Koch Strasse 50
Sirius Gutenberg Park
MainzRP55129
DEUT: +49 61315542860
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
26
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,816.40 | 58.90 | -0.66% |
| CAC 40 | 7,742.05 | 24.16 | -0.31% |
| DAX 40 | 24,077.10 | 16.81 | 0.07% |
| Dow JONES (US) | 43,906.96 | 116.33 | -0.26% |
| FTSE 100 | 8,946.01 | 7.69 | 0.09% |
| HKSE | 24,517.76 | 72.36 | -0.29% |
| NASDAQ | 20,602.59 | 75.21 | -0.36% |
| Nikkei 225 | 39,663.40 | 14.62 | -0.04% |
| NZX 50 Index | 12,754.59 | 64.96 | 0.51% |
| S&P 500 | 6,224.09 | 19.67 | -0.32% |
| S&P/ASX 200 | 8,561.80 | 68.50 | -0.79% |
| SSE Composite Index | 3,503.78 | 1.22 | -0.03% |